Lamin A/C (LMNA) is one of the most frequently mutated genes associated with dilated cardiomyopathy (DCM). DCM related to mutations in LMNA is a common inherited cardiomyopathy that is associated with systolic dysfunction and cardiac arrhythmias. Here we modelled the LMNA-related DCM in vitro using patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Electrophysiological studies showed that the mutant iPSC-CMs displayed aberrant calcium homeostasis that led to arrhythmias at the single-cell level. Mechanistically, we show that the plateletderived growth factor (PDGF) signalling pathway is activated in mutant iPSC-CMs compared to isogenic control iPSC-CMs. Conversely, pharmacological and molecular inhibition of the PDGF signalling pathway ameliorated the arrhythmic phenotypes of mutant iPSC-CMs in vitro. Taken together, our findings suggest that the activation of the PDGF pathway contributes to the pathogenesis of LMNA-related DCM and point to PDGF receptor-β (PDGFRB) as a potential therapeutic target.
DCM associated with mutations in LMNA (LMNA-related DCM) is an autosomal dominant disorder caused by mutations in the gene that encodes the lamin A/C proteins that constitute the major component of the nuclear envelope [1] [2] [3] . LMNA-related DCM accounts for 5-10% of cases of DCM and has an age-related penetrance with a typical onset 4, 5 between the ages of 30 and 40. In contrast to most other forms of familial DCM, sudden cardiac death may be the first manifestation of LMNA-related DCM even in the absence of systolic dysfunction, owing to malignant arrhythmias such as ventricular tachycardia and fibrillation [4] [5] [6] . However, the precise mechanisms that link the mutations in LMNA to increased arrhythmogenicity are unknown.
Modelling LMNA-related DCM with iPSC-CMs in vitro
We recruited a large family cohort, members of which carry a frameshift mutation in LMNA that leads to the early termination of translation (348-349insG; K117fs) (Extended Data Fig. 1a-c) . Three of the carriers (III-1, III-3 and III-9) presented with atrial fibrillation that progressed to atrioventricular block, ventricular tachycardia (Extended Data Fig. 1d , e) and DCM.
We generated multiple patient-specific iPSC lines using nonintegrating reprogramming methods 7, 8 and derived iPSC-CMs using a chemically defined protocol [8] [9] [10] to examine the electrophysiological properties at the single-cell level. We found that the LMNA-mutant iPSC-CMs (III-3, III-9, III-15 and III-17) exhibited proarrhythmic activity in both atrial-and ventricular-like iPSC-CMs compared to healthy controls (IV-1 and IV-2) ( Fig. 1a and Extended Data Fig. 1f, g ). Taken together, these data demonstrate that patient-specific iPSC-CMs recapitulate the disease phenotype associated with LMNA-related DCM in vitro.
Next, we generated a panel of isogenic lines that differed only in this mutation using the iPSC line derived from patient III-3 (who carried one wild-type and one mutant allele (WT/MUT)) through TALENmediated genome editing 11, 12 . Specifically, we corrected the LMNA mutation to the wild-type allele in the iPSCs (WT/cor-WT), inserted the K117fs mutation in the wild-type allele (ins-MUT/MUT) and generated a knockout iPSC line by targeting the start codon 11 (ATG site) of the wild-type allele (del-KO/MUT) ( Fig. 1b and Extended Data Fig. 2a-c) . We also introduced the K117fs mutation in the healthy control iPSC line (patient IV-1, who carried two wild-type alleles (WT/WT)) to generate a heterozygous mutant iPSC line (WT/ins-MUT). We generated iPSC-CMs from the isogenic lines and observed that the targeted gene correction rescued the electrophysiological abnormalities in WT/cor-WT-derived iPSC-CMs compared to parental WT/MUT, genomeedited ins-MUT/MUT and del-KO/MUT iPSC-CMs (Fig. 1c-g ). As expected, the insertion of the K117fs mutation in the line derived from the healthy control individual (WT/ins-MUT) induced arrhythmias (Extended Data Fig. 2d-g ). Together, these data suggest that LMNA K117fs is a pathogenic mutation that causes LMNA-related DCM.
As homeostasis of calcium ions (Ca 2+ ) is critical for excitationcontraction coupling in the heart 13, 14 , we analysed the intracellular Ca 2+ -handling properties of the isogenic iPSC-CMs. Abnormal Ca 2+ transients were observed in K117fs iPSC-CMs, whereas the control iPSC-CMs exhibited uniform Ca 2+ transients (Fig. 2a) . Furthermore, WT/ins-MUT iPSC-CMs displayed abnormal Ca 2+ transients when compared to the isogenic WT/WT iPSC-CMs (Fig. 2b) . Next, we recorded the calcium transient in the presence of tetrodotoxin, a sodium channel blocker, to inhibit any beating initiated at the plasma membrane 15, 16 . We observed spontaneous Ca 2+ cycling at very low extracellular Ca 2+ levels in WT/MUT iPSC-CMs in contrast to the Article reSeArcH minimal occurrence of Ca 2+ activity found in the isogeneic control line (WT/cor-WT), suggesting that abnormal calcium release from the sarcoplasmic reticulum occurred in the WT/MUT iPSC-CMs (Extended Data Fig. 3a-c) . Taken together, these findings demonstrated that the dysregulation of Ca 2+ in the sarcoplasmic reticulum is associated with the electrical abnormalities observed in K117fs iPSC-CMs.
Given that hyperphosphorylation of ryanodine receptor 2 (RYR2) by Ca 2+ /calmodulin-dependent kinase II (CAMK2) leads to arrhythmias related to delayed afterdepolarizations 17 , as documented in the LMNAmutant iPSC-CMs (Fig. 1d , e), we tested whether the activation of this pathway induces arrhythmias in K117fs iPSC-CMs. Notably, phosphorylated RYR2 (pRYR2) and phosphorylated CAMK2D (pCAMK2D) levels were significantly increased in K117fs iPSC-CMs (WT/MUT, ins-MUT/ MUT and del-KO/MUT) compared to the levels found in the isogenic control iPSC-CMs (WT/cor-WT) (Fig. 2c, d ). By contrast, expression levels of both CAMK2D and RYR2 mRNA were similar between isogenic control and K117fs iPSC-CMs (Extended Data Fig. 3d-g ). When the activation of CAMK2D was inhibited in K117fs iPSC-CMs using KN93, a specific CAMK2D inhibitor, we observed a significant decrease in the levels of pRYR2 and pCAMK2D as well as a significant decrease in abnormal Ca 2+ transients (22.22%, n = 81) compared to K117fs iPSC-CMs treated with vehicle (65.38%, n = 52) or the inactive analogue KN92 (65.30%, n = 49) ( Fig. 2e and Extended Data Fig. 3h-j) . Taken together, these data suggest that CAMK2-mediated RYR2 activation causes abnormal Ca 2+ handling and arrhythmias in K117fs iPSC-CMs.
Lamin A/C haploinsufficiency in mutant iPSC-CMs
Given that abnormalities in nuclear structures are associated with laminopathies 18 , we examined the integrity of the nuclear envelope in K117fs iPSC-CMs. Through immunostaining analyses, we demonstrated that K117fs iPSC-CMs display abnormal nuclear structures compared to isogenic controls ( Fig. 3a and Extended Data Fig. 4a-c) . Notably, the expression of lamin A/C proteins was significantly reduced in K117fs compared to isogenic control iPSC-CMs. Furthermore, the full-length or truncated lamin A/C were not detected in ins-MUT/MUT and del-KO/MUT iPSC-CMs (Fig. 3b , c and Extended Data Fig. 4d-f ). These data suggest that the K117fs mutation leads to lamin A/C haploinsufficiency. Furthermore, the total level of LMNA mRNA expression was significantly reduced in K117fs compared to isogenic control iPSC-CMs ( Fig. 3d and Extended Data Fig. 4g ). Nonsense-mediated mRNA decay (NMD) is a mechanism coupled to translation that selectively degrades mRNAs that contain premature translation-termination codons 19, 20 . To investigate whether NMD influences the expression levels of LMNA mRNA in K117fs iPSC-CMs, we assessed allele-specific expression of LMNA mRNA. We found that 97% and 3% of the total LMNA mRNA was expressed by the wild-type and the K117fs allele, respectively, in the K117fs iPSC-CMs (WT/MUT; III-3) (Fig. 3e and Extended Data Fig. 4h ). We observed a significant increase in the expression levels of the K117fs allele (18-37%) and the appearance of a 14-kDa band upon inhibition of the NMD pathway in K117fs iPSC-CMs ( Fig. 3f and Extended Data Fig. 4i, j) . In addition, the 14-kDa band was not detected in the isogenic control line (WT/cor-WT) after NMD inhibition (Extended Data Fig. 4k ), which suggests that the truncated lamin A/C is translated from the mutant LMNA mRNA. Collectively, these findings indicate that NMD-mediated degradation of mutant LMNA mRNA induces lamin A/C haploinsufficiency in K117fs iPSC-CMs. transients of control and mutant iPSC-CMs. The ratio of the fura-2 AM signal excited at 340 nm and 380 nm is shown (F 340 /F 380 ). b, The percentage of cell count that exhibit arrhythmic waveforms in control and mutant iPSC-CMs. c, d, Immunoblot analysis of the levels of pRYR2, RYR2, pCAMK2D and CAMK2D in control and mutant iPSC-CMs. Data are mean ± s.e.m.; a two-tailed Student's t-test was used to calculate P values; n = 3. e, The percentage of cell count that exhibit arrhythmic waveforms in mutant iPSC-CMs (III-3 WT/MUT) treated with 1 μM of KN92 or KN93 for 24 h. All traces were recorded for 20 s. The Ca 2+ transients shown in a were independently repeated as described in b with similar results. The immunoblot data in c were independently repeated twice with similar results.
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Increased open chromatin in mutant iPSC-CMs
Lamin A/C interacts with heterochromatin-rich genomic regions at the nuclear envelope called lamin-associated domains (LADs), which have an essential role in the organization of chromatin [21] [22] [23] [24] . We therefore postulate that lamin A/C haploinsufficiency could disturb chromatin distribution, leading to aberrant gene expression in K117fs iPSC-CMs. Using an assay for transposase-accessible chromatin with visualization (ATAC-see) 25 , we observed that the distribution of open chromatin was biased towards the nuclear periphery in K117fs iPSC-CMs, whereas isogenic control iPSC-CMs showed a uniform distribution throughout the nucleus (Extended Data Fig. 5a-g ).
To study whether lamin A/C haploinsufficiency results in an abnormal conformation of open chromatin, we investigated the relationship between LADs and gene activation 26, 27 (Extended Data  Fig. 6a) . We compared the LADs in isogenic iPSC-CMs and grouped these LADs into three categories: loss, overlapping and gain ( Fig. 4a and Extended Data Fig. 6b ). The genomic coverage, mean LAD length and numbers of LADs were similar in K117fs and isogenic control iPSC-CMs (Fig. 4b-d and Extended Data Fig. 6c-e) . Notably, the LADs that showed loss or gain were located in nearby overlapping regions in K117fs iPSC-CMs, which suggests that lamin A/C haploinsufficiency led to local changes in existing LADs (Fig. 4e) . Analysis of chromatin conformation and histone modifications showed that most of the gene promoters that resided in LADs were associated with increased open chromatin in K117fs iPSC-CMs compared to control iPSC-CMs ( Fig. 4g and Extended Data Fig. 6f, g ). Normalized assay for transposase accessible chromatin with high-throughput sequencing (ATAC-seq) and histone modification enrichment of each LAD were negatively correlated with enrichment by lamin A/C, and genes associated with LADs were more actively expressed in K117fs iPSCCMs compared to control iPSC-CMs (Fig. 4h-k and Extended Data Fig. 6h-k) . Moreover, histone H3 lysine-9 dimethylation (H3K9me2) in mutant iPSC-CMs was not equally distributed throughout the nuclear periphery and was less enriched in LADs region 28 (Extended Data Fig. 7a-e) . Collectively, these data indicate that lamin A/C haploinsufficiency causes local changes in LADs leading to transcriptional activation.
Notably, we also found that many of the genes located in the non-LAD region were highly upregulated in K117fs compared to control iPSC-CMs, although the distance to the nearest LAD did not affect their expression (Extended Data Fig. 8a, b) . The cooccurrence of transcription factors and ARCHS4 database analysis of differentially expressed genes located in non-LADs suggest that a prominent transcription factor of interest (PRRX1) that is located within a LAD may affect the abnormal expression of genes in non-LADs (Extended Data Fig. 8c-f) . These data suggest a potential mechanism through which the alteration of LADs in K117fs iPSC-CMs affects the transcriptional regulation of genes located in non-LADs.
The PDGF pathway links to arrhythmic phenotype
To identify additional potential target genes that are closely associated with the disease phenotype, we compared the transcriptomes of K117fs mutant and control iPSC-CMs. By comparing the total RNA expression of control iPSC-CMs versus K117fs iPSC-CMs, we found that most of the differentially expressed genes were upregulated in K117fs iPSC-CMs (III-3, 84.87%; IV-1, 70.80%) (Fig. 5a) . A cross-analysis of differentially expressed genes based on two different genetic backgrounds (III-3 and IV-1) identified 257 genes for which the expression in K117fs iPSC-CMs significantly differed from that in isogenic control iPSC-CMs (Fig. 5b) . As expected, 239 out of 257 genes (93%) were upregulated in K117fs iPSC-CMs compared to isogenic control iPSC-CMs (Fig. 5c ). Gene ontology (GO) enrichment analysis revealed that the upregulated genes in K117fs iPSC-CMs were functionally enriched in terms associated with platelet-derived growth factor (PDGF) binding arylsulfatase activity, protein binding involved in cell-matrix adhesion and PDGF receptor binding (Fig. 5d) . The ARCHS4 kinase 29 analysis also showed that the upregulated genes in K117fs iPSC-CMs were highly enriched in the PDGF pathway. . e, Digital droplet PCR analysis of allele-specific expression of LMNA in mutant iPSC-CMs treated with emetine (150 or 300 μg ml −1 for 6 h) and wortmannin (50 or 100 mM for 6 h). Data are mean ± s.d.; n = 2; statistical significance was calculated using a one-way analysis of variance (ANOVA). f, Immunoblot analysis of cell lysates from mutant iPSC-CMs treated with emetine and wortmannin. Two different batches of antibodies (E-1, lots A3118 (top) and G1413 (bottom)) were used. Red asterisks indicate the truncated lamin A/C (about 14 kDa in size). The signal intensity of the truncated lamin A/C is shown. The immunoblot data in b and f were independently repeated twice with similar results. c-e, Data are mean ± s.e.m.; statistical significance was calculated using one-way ANOVA. NS, not significant.
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The PDGF signalling is highly activated in smooth muscle and endothelial cells, and is initiated through the activation of two major receptors belonging to the PDGF receptor-α (PDGFRA) and PDGF receptor-β (PDGFRB) family 30 . During cardiomyocyte differentiation, PDGFRA and PDGFRB are highly upregulated in the early stages of differentiation but become downregulated after generating functional cardiomyocytes 31 (Extended Data Fig. 9a ). In particular, expression of PDGFRB mRNA and PDGFRB protein is low in adult iPSC-CMs and normal heart tissues, but can be increased by stress conditions 32, 33 , which suggests that the PDGF signalling pathway is silenced in cardiomyocytes under physiological conditions (Extended Data Fig. 9a-c) . However, we found that a significant increase in PDGFRB mRNA and protein expression occurred in K117fs iPSC-CMs compared to control iPSC-CMs ( Article reSeArcH the ATAC-seq analysis (Extended Data Fig. 9h , i). Consistent with our observations in iPSC-CMs, heart tissue samples from both patients with LMNA-related DCM showed lower LMNA expression and higher PDGFRB expression when compared to healthy control tissues (Extended Data Fig. 9j , k). Taken together, these data suggest that PDGFRB is epigenetically activated in K117fs iPSC-CMs. Next, we tested whether the abnormal activation of PDGFRB was directly linked to the arrhythmic phenotype that was observed in K117fs iPSC-CMs. Knockdown of PDGFRB expression in K117fs iPSCCMs by small interfering (si)RNA resulted in a reduced prevalence of abnormal Ca 2+ transients (23.28%, n = 72) compared to the treatment with scramble siRNA control (100%, n = 75) ( . 10g ). We also observed that the overexpression of PDGFRB resulted in upregulation of CAMK2D phosphorylation, inducing an arrhythmic phenotype in control iPSC-CMs (44.44%, TRPM4  HRC  CASQ1  ATP2B1  CAMK2D  TNNI3   TPM2  ACTA1  TNNC1  ITGB5  CSRP3  LMOD2  MYOM1  KCNH2  PGAM2  HRC  SLMAP  MYH11  SGCA  SSPN  ACTC1  TCAP transients for mutant iPSC-CMs treated with the PDGRB inhibitors crenolanib (CB) (100 nM) and sunitinib (SB) (500 nM) for 24 h. k, Immunoblot analysis of pCAMK2D and CAMK2D protein levels after treatment with dimethyl sulfoxide (DMSO), crenolanib or sunitinib. The analyses were independently repeated twice with similar results. l, Hierarchical clustering of amplicon-based sequencing (AmpliSeq) transcriptome data; analysed by one-way ANOVA (P = 0.05). Two different K117fs iPSC-CMs lines treated with crenolanib, sunitinib or DMSO were analysed by RNAseq. The total number of genes is 915. m, n, GO analysis identified a set of genes that was related with muscle contraction and regulation of cardiac conduction. f, g, Data are mean ± s.e.m.; statistical significance was calculated using one-way ANOVA. The Ca 2+ transients shown in h were independently repeated as described in i with similar results.
Article reSeArcH n = 90) (Extended Data Fig. 10h-j) . These data indicate that the abnormal activation of PDGFRB contributes to the arrhythmic phenotype observed in K117fs iPSC-CMs.
To test the effects of the abnormal activation of PDGFRB on the gene-expression profile of K117fs iPSC-CMs, we next evaluated how treatment with crenolanib and sunitinib affected the transcriptome of K117fs iPSC-CMs. We identified a total of 910 genes that were differentially expressed between the treated and the untreated groups (Fig. 5l) . GO term analysis of downregulated genes in the treated groups showed a high enrichment of genes related to heart functions, including muscle contraction, the regulation of cardiac conduction and ion transport (Fig. 5m, n and Extended Data Fig. 11a, b) . We confirmed significant changes in the expression of genes related to cardiac muscle contraction and actin-mediated cell contraction through the knockdown of PDGFRB in K117fs iPSC-CMs (Extended Data Fig. 11c-e) . We found that there were no differences in the lamin A/C level or the nuclear structure after treatment with crenolanib or sunitinib (Extended Data Fig. 11f-h ). Taken together, these data confirm that the lamin A/C haploinsufficiency causes the abnormal activation of the PDGF signalling pathway, leading to the development of arrhythmias in LMNA-related DCM.
Discussion
Lamin A/C proteins are key components of heterochromatin conformation and the gene-silencing machinery, and are expressed in a cell-type-specific manner 23, 34, 35 . Here we elucidate how lamin A/C haploinsufficiency affects chromatin conformation and the geneexpression profile of LMNA-mutant iPSC-CMs. Furthermore, we demonstrate that the inhibition of the PDGF pathway ameliorates the arrhythmic phenotype of K117fs iPSC-CMs, suggesting a novel therapeutic target for the treatment of LMNA-related DCM (Extended Data Fig. 12 ). Our study suggests that several FDA-approved PDGFRB inhibitors-such as sunitinib, sorafinib and axitinib-may be repurposed for this condition. However, our previous study using a human iPSC-CM platform also revealed dose-dependent cardiac toxicity that is implicated in most tyrosine kinase inhibitors 36 . Therefore, further studies are warranted to identify the proper dosage or alternatives to these inhibitors that can be safely used in vivo to optimally alter the PDGF signalling pathway and prevent the fatal arrhythmias that are frequently observed in patients with LMNA-related DCM.
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Methods
No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators who performed electrophysiological tests and Ca 2+ imaging analysis were blinded to group allocation during experiments and data collection. The studies comply with all ethical regulations. Patient recruitment. The fibroblasts, PBMCs and heart tissues were obtained from patients using IRB-approved protocols at Stanford University (protocols 17576 and 29904). Informed consent was obtained from all patients who were included in our study. Clinical features of patients are described in the Extended Data Fig. 1d . Culture and maintenance of iPSCs. iPSC lines were maintained in a chemically defined Essential 8 (E8 medium) medium (Life Technologies) on Matrigel-coated (BD Bioscience) plates at 37 °C with 5% (v/v) CO 2 . Pluripotency marker analysis. Human iPSC colonies grown in Matrigel-coated 8-well chamber glasses (Thermo Scientific) were fixed using 4% paraformaldehyde and permeabilized with 0.5% Triton X-100. After blocking samples with 5% goat serum in PBST (PBS with 0.1% Tween-20), cells were stained with mouse anti-SSEA4 (R&D systems), rabbit anti-OCT3/4 (Santa Cruz Biotechnology), rabbit anti-NANOG (Santa Cruz Biotechnology) and mouse anti-SOX2 (R&D systems) antibodies. Cells were then incubated with Alexa Fluor-conjugated secondary antibodies (Life Technologies) and Hoechst 33342 (Life Technologies) to visualize the specific stains. Image acquisition was performed on an Eclipse 80i fluorescence microscope (Nikon Instruments). TALEN-mediated homologous recombination. TALEN pair vectors were designed and constructed using the rapid TALEN assembly system as previously described 11 . In brief, 500 base-pair (bp) fragments of wild-type LMNA exon 1 and adjacent intronic sequences were synthesized as GeneArt String DNA fragments (Life Technologies) to make left and right homologous arms, and cloned into PB-MV1Puro-TK vectors (Transposagen), as previously described 12 . Two silent mutations in the homologous arms were inserted to avoid recleavage of the genomic sequence. Both TALEN pairs and targeting vectors were delivered into iPSCs by nucleofection using P3 Primary Cell 4D-Nucleofector X Kit (Lonza). Afterwards, cells with the correct targeting vector integration were selected by puromycin (Life Technologies) and genotyped. To excise the selection cassette, transient expression of piggyBac transposase was performed by transfection of excising piggyBac transposase mRNA (Transposagen) using Lipofectamine MessengerMAX (LifeTechnologies). After negative selection using ganciclovir (Sigma Aldrich), the established clones were genotyped by PCR and bidirectional direct sequencing. TALEN-mediated non-homologous end joining. TALEN pair vectors were designed and constructed using the rapid TALEN assembly system as previously described 11, 12 and were delivered into iPSCs by nucleofection using the P3 Primary Cell 4D-Nucleofector X Kit (Lonza). Subsequently, 45 h after nucleofection, transfected cells were enriched by fluorescence-activated cell sorting (FACS) and established clones were genotyped by PCR and bidirectional direct sequencing. Off-target detection. Genomic DNA was extracted from gene-edited iPSC clones using the DNeasy Blood & Tissue Kit (Qiagen). The potential TALEN off-target sites were predicted in silico based on sequence homology using the bioinformatics tool PROGNOS. The top 20 targets were investigated by DNA sequencing. The primers designed by PROGNOS were used to amplify the genomic regions of putative off-target sites by PCR. Each PCR reaction contained 1.25 units of Prime STARGXL DNA Polymerase (Clontech) and 50 ng of genomic DNA (total volume 20 μl). The PCR products were analysed by Sanger sequencing and sequencing reads were aligned to the wild-type sequence obtained from the parental iPSC line. Immunocytochemistry. Cells grown on coverslips were fixed using 4% paraformaldehyde, permeabilized with 0.5% Triton X-100, incubated with primary antibodies and Hoechst 33342, and detected using Alexa Fluor-conjugated secondary antibodies. Primary antibodies include rabbit anti-cardiac troponin T (Abcam), mouse anti-cardiac troponin T (Thermo Scientific), mouse anti-sarcomeric α-actinin (Sigma-Aldrich), goat anti-LMNA (Santa Cruz) and rabbit anti-LMNA (Santa Cruz) antibodies. Image acquisition was performed on an Eclipse 80i fluorescence microscope, a confocal microscope (Carl Zeiss, LSM 510 Meta) and ZEN software (Carl Zeiss). Reverse transcription and quantitative PCR. Total mRNA was isolated from iPSC-CMs using the Qiagen miRNeasy Mini kit. Subsequently, 1 μg of RNA was used to synthesize cDNA using the iScript cDNA Synthesis kit (Bio-Rad). Then, 0.25 μl of the reaction was used to quantify gene expression by qPCR using TaqMan Universal PCR Master Mix. Expression values were normalized to the average expression of the housekeeping gene 18S. Western blotting. Proteins were resolved by SDS-PAGE and were transferred to 0.45-μm nitrocellulose membranes (Bio-Rad) using a mini Bio-Rad Mini PROTEAN 3 Cell system in NuPAGE transfer buffer (Life Technologies). The membrane was then blocked in Membrane Blocking Solution (Life Technologies) and incubated with primary antibodies overnight at 4 °C. Blots were incubated with the appropriate secondary antibodies for 1 h at room temperature and visualized using the ECL Western Blotting Analysis System (GE Healthcare). Primary antibodies used were mouse anti-LMNA (Santa Cruz), rabbit anti-LMNA (Santa Cruz), CAMK2D (Abcam), PDGFRB (Cell Signaling), RYR2 (Abcam), pRYR2 (D. M. Bers laboratory) and HRP-conjugated α-tubulin (Cell Signaling). Patch-clamp recordings. Whole-cell action potentials were recorded using a standard patch-clamp technique. In brief, cultured iPSC-CMs were plated on No. 1 18-mm glass coverslips (Warner Instruments) coated with Matrigel, placed in a RC-26C recording chamber (Warner Instruments) and mounted onto the stage of an inverted microscope (Nikon). The chamber was continuously perfused with warm (35-37 °C) extracellular solution (pH 7.4) of the following composition: NaCl (140 mM), KCl (5.4 mM), CaCl 2 (1.8 mM), MgCl 2 (1 mM), HEPES (10 mM) and glucose (10 mM); pH was adjusted to 7.4 with NaOH. Glass micropipettes were fabricated from standard wall borosilicate glass capillary tubes (Sutter BF 100-50-10, Sutter Instruments) using a programmable puller (P-97; Sutter Instruments) and filled with the following intracellular solution (in mM): 120 KCl, 1.0 MgCl 2 , 10 HEPES, 10 EGTA and 3 Mg-ATP (pH 7.2). A single beating cardiomyocyte was selected and action potentials were recorded in whole-cell current-clamp mode using an EPC-10 patch-clamp amplifier (HEKA). Data were acquired using Patch Master software (HEKA) and digitized at 1.0 kHz. Differentiation of iPSC-CMs. iPSCs were grown to 90% confluence and subsequently differentiated into beating cardiomyocytes, using a small-molecule-based monolayer method that has previously been described 10 . After ten days of cardiac differentiation, iPSC-CM monolayers were purified using RPMI-1640 without glucose (Life Technologies) and with B-27 supplement (Life Technologies). The non-glucose culture medium was changed every two days. After five days, iPSC-CMs were reseeded on Matrigel-coated plates in a culture medium containing glucose. siRNA-mediated knockdown. Gene knockdown experiments were performed using Lipofectamine RNAiMax (Life Technologies) according to the manufacturer's instructions. Cells were transfected with either scramble siRNA or siRNA against PDGFRB (SilencerRSelect, ThermoFisher, 25 nM per well, 4390824) for 48 h before being subjected to subsequent downstream analyses. Treatment with NMD inhibitors. The potent NMD inhibitors emetine and wortmannin (Sigma-Aldrich) were dissolved in water and DMSO, respectively. An equal concentration of solvent (water or DMSO) was used as the control. iPSCCMs were treated with emetine or wortmannin for 6 h before the experiment. Treatment with PDGFRB inhibitors. The PDGFRB inhibitors sunitinib and CP-868596 (Selleckchem) were dissolved in DMSO. An equal concentration of solvent (DMSO) was used as the control. iPSC-CMs were treated with sunitinib or CP-868596 for 48 h before the experiment. Treatment with CAMK2D inhibitors. The active CAMK2D inhibitor (KN93) and inactive CAMK2D inhibitor (KN92) were dissolved in DMSO. iPSC-CMs were treated with KN92 or KN93 for 24 h before the experiment. Droplet digital PCR. Total RNA was extracted from iPSC-CMs at day 30 post-differentiation using the miRNeasy Mini Kit (QIAGEN) and cDNA preparation was carried out using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories). The concentration of cDNA was reduced to about 0.2 ng μl −1 RNA equivalent, and 1 ng (5 μl of 0.2 ng μl −1 ) of RNA-equivalent cDNA was mixed with primers, probes and ddPCR Supermix reaction (total volume 20 μl). The final concentrations of the primers and the probe were 900 nM and 500 nM, respectively. The following primers and probes for discriminating allelic expression of LMNA K117 (wild-type allele) from K117fs (mutant allele) were used: forward primer, 5′-GCAAGACCCTTGACTCAGTA-3′; reverse primer, 5′-CTCCTTGGAGTTCAGCAG-3′; wild-type probe: 5′(6-FAM)-TGCGCGCTTTCAGCTCCTTAA-(Blackhole Quencher)3′; and mutant probe, 5′(HEX)-TGCGCGCTTTCCAGCTCCT-(Blackhole Quencher)3′. Droplet formation was carried out using a QX100 droplet generator. A rubber gasket is placed over the cartridge and loaded into the droplet generator. The emulsion (35 μl in volume) was then slowly transferred using a multichannel pipette to a 96-Well twin. tec PCR Plate (Eppendorf). The plate was heat-sealed with foil and the emulsion was cycled to end point per the manufacturer's protocol with an annealing temperature at 61 °C. Finally, the samples were analysed using a BioRad QX100 reader. Ca 2+ imaging. iPSC-CMs seeded on a glass coverslip for 5-7 days were loaded with the cell-permeable calcium-sensitive dye fura-2 AM (2 μmol l −1 ) for 20 min. After 15 min of washing in 1.8 mmol l −1 Ca 2+ -Tyrode (135 mmol l −1 NaCl, 4 mmol l −1 KCl, 1 mmol l −1 MgCl 2 , 5 mmol l −1 glucose and 10 mmol l −1 HEPES, pH 7.4) buffer to allow de-esterification, coverslips were mounted on the stage of an inverted epifluorescence microscope (Nikon Eclipse Ti-S). iPSC-CMs were field-stimulated at 0.5 Hz with a pulse duration of 10 ms. Fura-2-AM-loaded cells were excited at both 340 and 380 nm, and the emission fluorescence signal was collected at 510 nm as previously described 37 . Changes in fluorescence signal were measured using the NIS Elements AR software, which permits the recording of multiple cells in one view. Intracellular calcium changes were expressed as changes in the ratio R = F 340 /F 380 and the calcium transient waves were analysed using a previously published method 38 .
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Measuring abnormal calcium release from the sarcoplasmic reticulum. Both patient-and healthy individual-derived iPSC-CMs were seeded on coverslips as single cells. After 3-4 days of recovery, the cells were loaded with 5 μM Fluo-4 AM at 37 °C for 10 min and then washed with Tyrode's solution three times. Ca 2+ release events were recorded with a Carl Zeiss confocal (710) in line-scanning mode (512 pixels × 1,920 lines). The extracellular media were prepared with sequential increases of Ca 2+ concentration (0, 0.5, 1, 2 and 5 mM), and were used to treat iPSC-CMs during the recording. The Ca 2+ imaging data were displayed and analysed using Image J. Measuring sarcomeric alignments. Immunostaining images of iPSC-CMs were viewed with Image J, and the fluorescent signals along the sarcomere structure were pulled out. A custom-made Interactive Digital Language algorithm was used to analyse the regularity of sarcomere signal distribution with fast Fourier transformation (FFT). The sarcomere length and the regularity of sarcomere distribution were indicated as the position and the height of the first main peak after FFT data processing. ChIP-seq. LMNA antibodies (Santa Cruz Biotechnology; sc-376248 and Abcam; 8984) were incubated with Dynabeads (Life Technologies; 10003D) for 12 h at 4 °C. A small portion of the crosslinked, sheared chromatin was saved as the input, and the remainder was used for immunoprecipitation using antibody-conjugated Dynabeads. After overnight incubation at 4 °C, the incubated beads were rinsed with sonication buffer (50 mM HEPES pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 0.5 mM PMSF), a high-salt buffer (50 mM HEPES pH 7.9, 500 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 0.5 mM PMSF) and a LiCl buffer (20 mM Tris, pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% sodium deoxycholate, 0.5 mM PMSF). The washed beads were incubated with elution buffer (50 mM Tris, pH 8.0, 1 mM EDTA, 1% SDS, 50 mM NaHCO 3 ) for 1 h at 65 °C and then de-crosslinked with 5 M NaCl overnight at 65 °C. The immunoprecipitated DNA was treated with RNase A and proteinase K and purified by ChIP DNA Clean and Concentrator (Zymo Research; D5205). The raw sequencing data were analysed as previously described 39 .
RNA-seq.
For each sample in the whole-transcriptome sequencing library, 60-80 million 75-bp paired-end reads were acquired from the sequencer. Base quality of raw reads is high after checking with FastQC 0.11.4. Using STAR 2.5.1b, we aligned the reads to the human reference genome (hg19), with splice junctions defined by the GTF file downloaded from UCSC. On average, 92% of reads were aligned to the reference genome, and 83% of reads were uniquely aligned to the reference genome. Gene expression was determined by calculating the FPKM using Cufflinks 2.2.1. In addition, Cufflinks was used to determine differential expression between each two conditions. ATAC-seq. The samples were treated and processed as previously described 40 . In brief, 100,000 cells were centrifuged at 500g for 5 min at room temperature. The cell pellet was resuspended in 50 ml lysis buffer (10 mM Tris-Cl pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 0.01% Igepal CA-630) and centrifuged immediately at 500g for 10 min at 4 °C. The cell pellet was resuspended in 50 ml transposase mixture (25 μl 2× TD buffer, 22.5 μl, dH 2 O and 2.5 μl Illumina Tn5 transposase or 100 nM (final concentration) Atto-590-labelled in-house-generated Tn5) and incubated at 37 °C for 30 min. After transposition, the mixture was purified with the Qiagen Mini purification kit and eluted in 10 μl Qiagen EB elution buffer. Sequencing libraries were prepared following the original ATAC-seq protocol 40 . The sequencing was performed on Illumina NextSeq at the Stanford Functional Genomics Facility. ATAC-seq reads were trimmed of adapters and then mapped to hg19 genome assembly using Bowtie 2 41 . Following quality control to remove duplicate reads, average read intensities were calculated with the aid of deepTools 42 and R/Bioconductor (v.3.2.1) 43 . Promoter regions were defined as ±1 kb around the hg19 gene transcription start site coordinates unless otherwise stated. ATAC-see. The samples were treated and processed as previously described 25 . In brief, iPSC-CMs were fixed with 1% formaldehyde (Sigma) for 10 min and quenched with 0.125 M glycine for 5 min at room temperature. After fixation, the cells (either growing on slides or centrifuged on glass slides with Cytospin) were permeabilized with a lysis buffer (10 mM Tris-Cl pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 0.01% Igepal CA-630) for 10 min at room temperature. After permeabilization, the slides were rinsed in PBS twice and placed in a humid chamber box at 37 °C. The transposase mixture solution (25 μl 2× TD buffer, final concentration of 100 nM Tn5-ATTO-59ON, adding dH 2 O up to 50 μl) was added to the slide and incubated for 30 min at 37 °C. After the transposase reaction, slides were washed with PBS containing 0.01% SDS and 50 mM EDTA for 15 min three times at 55 °C. After washing, slides were mounted using Vectashield with DAPI (H-1200, Vector Laboratories). Fluorescence images were captured on a confocal microscope equipped with a 40× oil-immersion lens. Fluorescent intensity profiles of DAPI and ATAC were exported using ZEN (Zeiss). To find out whether the LMNA mutation led to the specific re-distribution of the epigenetic histone markers in the iPSC-CMs, the correlation between ATAC-see and DAPI signal of each nucleus was calculated using the Pearson correlation method. Image analysis was conducted using Graphpad Prism v.7.0. RNA-seq and ChIP-seq analysis. FastQC (v.0.11.5) and MultiQC (v.1.3) were used to assess read quality. Adaptor and quality trimming of reads were performed with trimmomatic (v.0.36). Reads were mapped to the hg19 reference genome using STAR (v.2.5.3a) with ENCODE long RNA-seq parameters. Uniquely mapped reads were filtered for and bigWig files were generated with samtools (v. 1.4) . FPKM values and differentially expressed genes were obtained using cuffdiff (v.2.2.1). ChIP-seq data were processed using the AQUAS pipeline from the Kundaje laboratory at Stanford University (https://github.com/kundajelab/chip-seqpipeline2), which has an end-to-end implementation of the ENCODE (phase 3) ChIP-seq pipeline. Default parameters were used with the exception of specifying '-type histone -species hg19' . Before LAD detection of LMNA data, duplicate reads were removed with 'mark duplicates' from Picard tools (v.2.17.3) and 'DownsampleSam' was used to downsample the larger of each pair of aligned input and ChIP read files, giving each pair the same read depth and avoiding normalization bias. LAD detection and analysis. Lamin A/C binding data were analysed using Enriched Domain Detector 39 (v.1.0) with an 11-kb bin size, gap penalty of 5, and FDR-adjusted significance threshold of P < 0.05. Gains, losses and intersections in LADs between control and mutant cells were tallied using bedtools (v.2.27.1). Gene-expression changes within each category of LADs (gain, loss or shared in mutant and control) based on RNA-seq data were compared in R v.3.2.1 and Bioconductor 43 using the iRanges and GenomicRanges packages 44 . In deciding whether a gene overlaps with each category, the union of called peaks from the lamin A/C ChIP-seq of two antibodies and the intersection of two cell lines were used. A gene is considered to reside in a particular LAD if any of its hg19-annotated transcription start sites overlaps with the LAD range by genomic coordinates. In cases of ambiguity, intersection (shared between control and mutant cells) regions take precedence over gain and loss regions. ATAC-seq read intensities within each LAD category around genomic features, including transcription start sites and transcription end sites, were visualized using deepTools 42 with feature coordinates from hg19 annotations. Statistical analyses. Data were expressed as mean ± s.e.m. Immunoblots are representative of at least two independent experiments. All other experiments are the average of at least 2 independent assays, and for cell number calculations in immunostaining assays, at least 100 cells per sample were counted for each independent experiment. Statistical analyses were performed using GraphPad Prism (v.6.0e). An unpaired two-tailed Student's t-test was used to calculate significant differences between two groups. Multiple comparison correction analysis was performed using one-way ANOVA followed by Tukey's post hoc HSD test. P < 0.05 was considered statistically significant. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
Data are available from the Gene Expression Omnibus (GEO; GSE118885). Fig. 2 | The mutation in LMNA is a cause of the arrhythmic phenotype in LMNA-mutant iPSC-CMs. a, Gene-editing strategy using the TALEN method. The piggyBac system was used to generate isogenic lines as previously described 11, 12 . b, Genotyping of geneedited isogenic lines (III-3 corrected, insertion, deletion; IV-1 insertion). For LMNA del-KO/MUT, we used TALEN pairs that target the start codon of LMNA. Genotyping showed the C insertion in the wild-type allele that leads early stop codon. c, Immunostaining of NANOG (red, left), POU5F1 (red, middle) and SOX2 (red, right) in iPSC lines. Blue, DAPI. Scale bars, different clones of control and mutant iPSC-CMs. Two different antibodies that recognize the N terminus of lamin A/C were used. GAPDH was used as loading control. g, Relative mRNA expression of total LMNA in control and mutant iPSC-CMs. Data are mean ± s.e.m.; a two-tailed Student's t-test was used to calculate P values; the value above the line indicates significance; n = 10 (WT/WT), n = 7 (WT/ins-MUT). h, Confirmation of allele-specific primers using plasmid carrying wild-type LMNA or mutant LMNA. Digital PCR using allele-specific primers detected the ratio of wild-type/mutant LMNA, which was consistent with the ratio of wild-type/mutant plasmids. Data are mean ± s. was used for data analysis. f, g, Average peak intensity of H3K4me3 and H3K27me3 of each LAD. n = 184 (loss), n = 370 (overlapping), n = 184 (gain) for H3K4me3; n = 273 (loss), n = 504 (overlapping), n = 273 (gain) for H3K27me3. Data are mean and minimum to maximum; Wilcoxon matched-pairs signed-rank test was used to calculate P values. h, Scatter plot of normalized lamin A/C, ATAC and histone marker (H3K4me3 and H3K27me3) enrichment of each LAD. The y axis shows the log 2 -transformed relative normalized lamin A/C enrichment of each LAD in mutant iPSC-CMs compared to control iPSC-CMs. The x axis shows the log 2 -transformed relative normalized ATAC and histone marks enrichment of each LAD in mutant iPSC-CMs compared with control iPSC-CMs. Each data point represents one LAD. The statistical significance was obtained using one-way ANOVA; n = 587 for sc-376248 and n = 585 for Abcam 8984. i, Percentage of differentially expressed genes in mutant iPSC-CMs compared to control iPSC-CMs. j, Number of differentially expressed genes located in mutant iPSC-CMs compared to control iPSC-CMs. (FDR-adjusted P < 0.01; log 2 -transformed fold change in expression of >1 or <−1). k, Distribution of log 2 -transformed fold change in FPKM in control and mutant iPSC-CMs. A non-parametric Kruskal-Wallis (testing for two-sided differences) followed by Dunn's post hoc test was used to adjust for multiple comparisons; n = 266 (gain), n = 8171 (non-LADs), n = 835 (overlapping), n = 206 (loss). The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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